



Eiger BioPharmaceuticals to Participate in September Conferences

PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September:

- *Baird 2019 Global Healthcare Conference at the InterContinental Barclay in New York City. Eiger will present a corporate update with a live webcast on September 4, 9:05-9:35 PM ET. Eiger will host one-on-one meetings.*
- *CITI 14th Annual Biotech Conference at the Four Seasons Hotel in Boston on September 5. Eiger will host one-on-one meetings.*
- *H.C. Wainwright Global Investment Conference at the Lotte New York Hotel in New York City. Eiger will present a corporate update with a live webcast on September 10, 3:00-3:25 PM ET. Eiger will host one-on-one meetings.*
- *Ladenburg Thalmann 2019 Healthcare Conference at Sofitel Hotel in New York City. Eiger will present a corporate update with a live webcast on September 24, 12:00-12:25 PM ET. Eiger will host one-on-one meetings.*

The live webcast of the Baird, H.C. Wainwright, and Ladenburg presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

About Eiger

Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.

The Company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward Phase 3 for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors: Ingrid Choong, PhD

Email: ichoong@eigerbio.com

Phone: 1-650-619-6115

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-september-conferences-300909355.html>

SOURCE Eiger BioPharmaceuticals, Inc.

